It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
B7H3, a cell surface protein often associated with higher grade solid tumors of various origins, is an attractive therapeutic target due to its frequent upregulated expression relative to normal tissue. In a large cohort of treatment-resistant, metastatic castrate resistant prostate cancer (mPC) patient derived xenografts and organoids, we present a comprehensive therapeutic and biomarker analysis. The 26 models tested encompass the heterogeneous genomic and histological categories of clinical mPC. In vitro and in vivo treatment with an anti-B7H3 targeted antibody conjugated to a pyrrolobenzodiazepine (PBD) cytotoxic agent were efficacious in 70% of models. All models expressed some B7H3 protein, the levels of which did not correlate with responses. Underlying susceptibilities to B7H3-PBD-ADC exposure were observed as multiple imperfectly overlapping classes of biomarkers, unrelated to androgen receptor dependence and substantially expanded beyond current homologous repair deficiencies. RB1 deficiency and/or replication stress, particularly prominent in small cell neuroendocrine prostate cancer (SCNPC), predicted responsiveness. The presence of SLFN11 in SCNPC and adenocarcinoma models correlated perfectly with vulnerability, although an absence of SLFN11 was not predictive. Of particular interest, an elevated interferon signature in adenocarcinomas, associated with alteration of wild type TP53, was quantitatively correlated with responsiveness. Finally, we also observed that susceptible models uniquely associated with the loss of select downstream DNA repair proteins. The above biomarkers are expressed in toto in about 70% of mPC clinical samples, suggesting broad potential for mechanistically complementary treatment of tumors escaping current regimens.
Competing Interest Statement
Peter S. Nelson has served as a paid advisor to Janssen, Bristol Myers Squibb and Pfizer and received research funding from Janssen for work unrelated to the present study. Eva Corey received research funding under institutional SRA from the following companies for work unrelated to the present study - Arvinas, Janssen Research and Development, Bayer Pharmaceuticals, KronosBio, Forma Pharmaceutics, Foghorn, MacroGenics, AstraZeneca, Gilead, Sanofi, AbbVie, and GSK. Elaine M Hurt is an employee and stockholder of AstraZeneca. All other authors declare no competing interests.
Footnotes
* 1) Title of the manuscript 2) Acknowledgments and competing interests
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer